Synthesis of telmisartan impurity B

Area of Science:

• Pharmaceutical Chemistry
• Analytical Chemistry
• Organic Synthesis

Background:

• Telmisartan is a widely used antihypertensive medication, functioning as an angiotensin II receptor (AT1) antagonist.
• The European Pharmacopoeia specifies seven impurities for Telmisartan quality control.
• Telmisartan Impurity B is commercially unavailable, and its synthesis has not been previously reported.

Purpose of the Study:

• To achieve the first-time synthesis of Telmisartan Impurity B.
• To provide a reliable method for obtaining Telmisartan Impurity B for analytical standards.
• To support the quality control and manufacturing processes of Telmisartan.

Main Methods:

• Development and execution of a novel synthetic route for Telmisartan Impurity B.
• Structural elucidation of the synthesized Impurity B using advanced spectroscopic techniques.
• Characterization through proton Nuclear Magnetic Resonance (1H NMR), carbon Nuclear Magnetic Resonance (13C NMR), and Mass Spectrometry (MS).

Main Results:

• Successful first-time synthesis of Telmisartan Impurity B.
• Confirmation of the synthesized impurity's structure using 1H NMR, 13C NMR, and MS data.
• Availability of a characterized standard for Telmisartan Impurity B.

Conclusions:

• The reported synthesis provides a crucial method for obtaining Telmisartan Impurity B.
• This achievement is vital for enhancing the quality control and manufacturing standards of Telmisartan.
• The availability of Impurity B will facilitate more rigorous testing and ensure the safety of the antihypertensive drug.